Monthly Prescribing Reference

Opsynvi, a Single-Tablet Combo Therapy for PAH, Gets FDA Approval

Opsynvi is a combination of macitentan, an endothelin receptor antagonist, and tadalafil, a phosphodiesterase 5 inhibitor. The Food and Drug Administration (FDA) has approved Opsynvi ® (macitentan and ...
Seeking Alpha

U.S. FDA Approves OPSYNVI® (macitentan and tadalafil) as the First and Only Once-Daily Single-Tablet Combination Therapy for Patients with Pulmonary Arterial Hypertension (PAH)

OPSYNVI ® combines two proven treatments with established efficacy and safety profiles into one tablet to be taken once daily, offering an option that helps to support the implementation of clinical ...
Healio

FDA approves combination therapy tablet for pulmonary arterial hypertension

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Opsynvi, a once-daily tablet that includes both macitentan and tadalafil, to treat adults ...
Healio

Combination macitentan, tadalafil tablet improves exercise capacity in PAH

Please provide your email address to receive an email when new articles are posted on . A prior study found that a combination macitentan and tadalafil tablet increased 6-minute walk distance at 16 ...
MedPage Today

Fixed-Dose Macitentan/Tadalafil Combo Gets FDA Approval for PAH

FDA approved macitentan/tadalafil (Opsynvi) as the first single-tablet combination therapy targeting multiple pathways for pulmonary arterial hypertension (PAH), Johnson & Johnson announced. The fixed ...
The American Journal of Managed Care

FDA Approves Macitentan, Tadalafil Combination Tablet for Pulmonary Arterial Hypertension

The approval, which marks the first for a once-daily, single-tablet combination therapy for pulmonary arterial hypertension, is based on findings from the phase 3 A DUE study. The combination is ...